SEARCH

SEARCH BY CITATION

References

  • BOTREL, M.A., HAAK, T., LEGRAND, C., CONCORDET, D., CHEVALIER, R. & TOUTAIN, P.L. (1994). Quantitative evaluation of an experimental inflammation induced with Freund's complete adjuvant in dogs. J. Pharmacol. Toxicol. Methods, 32, 6371.
  • BROWN, R.D., KEARNS, G.L. & WILSON, J.T. (1998). Integrated pharmacokinetic–pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. J. Pharmacol. Biopharm., 26, 559579.
  • BUSCH, U., SCHMID, J., HEINZEL, G., SCHMAUS, H., BAIERL, J., HUBER, C. & ROTH, W. (1998). Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos., 26, 576584.
  • DAYNEKA, N.L., GARG, V. & JUSKO, W.J. (1993). Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacol. Kinet. Biopharm., 21, 457478.
  • DIRIG, D.M., ISAKSON, P.C. & YAKSH, T.L. (1998). Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J. Pharmacol. Exp. Ther., 285, 10311038.
  • ENGELHARDT, G. (1996). Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br. J. Rheumatol., 35 (Suppl 1), 412.
  • ENGELHARDT, G., HOMMA, D., SCHLEGEL, K., UTZMANN, R. & SCHNITZLER, C. (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res., 44, 423433.
  • FLORES-MURRIETA, F.J., KO, H.C., FLORES-ACEVEDO, D.M., LOPEZ-MUNOZ, F.J., JUSKO, W.J., SALE, M.E. & CASTANEDA-HERNANDEZ, G. (1998). Pharmacokinetic–pharmacodynamic modelling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. J. Pharmacokinet. Biopharm., 26, 547557.
  • FRANCISCHI, J.N., CHAVES, C.T., MOURA, A.C., LIMA, A.S., ROCHA, O.A., FERREIRA-ALVES, D.L. & BAKHLE, Y.S. (2002). Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br. J. Pharmacol., 137, 837844.
  • GIRAUDEL, J.M., DIQUELOU, A., LEES, P. & TOUTAIN, P.L. (2005a). Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs. J. Vet. Pharmacol. Ther., 28, 275285.
  • GIRAUDEL, J.M., TOUTAIN, P.L. & LEES, P. (2005b). Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and application for predicting the selectivity of NSAIDs in the cat. Am. J. Vet. Res., 66, 700709.
  • GRANADOS-SOTO, V., LOPEZ-MUNOZ, F.J., HONG, E. & FLORES-MURRIETA, F.J. (1995). Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. J. Pharmacol. Exp. Ther., 272, 352356.
  • HOLSAPPLE, M.P. & YIM, G.K. (1984). Therapeutic reduction of ongoing carrageenin-induced inflammation by lipoxygenase, but not cyclooxygenase inhibitors. Inflammation, 8, 223230.
  • JOSA, M., URIZAR, J.P., RAPADO, J., DIOS-VIEITEZ, C., CASTANEDA-HERNANDEZ, G., FLORES-MURRIETA, F., RENEDO, M.J. & TROCONIZ, I.F. (2001). Pharmacokinetic/pharmacodynamic modelling of antipyretic and anti-inflammatory effects of naproxen in the rat. J. Pharmacol. Exp. Ther., 297, 198205.
  • KESSLER, F., SCHMIDT, K.L. & RUSCH, D. (1983). Thermometry in experimental inflammation. I. Studies on the circadian rhythm of the paw temperature in healthy rats and temperature behavior in acute inflammation after injection of kaolin, carrageenin and dextran. Z. Rheumatol., 42, 337342.
  • KOPPERT, W., WEHRFRITZ, A., KORBER, N., SITTL, R., ALBRECHT, S., SCHUTTLER, J. & SCHMELZ, M. (2004). The cyclooxygenase isoenzyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain, 108, 148153.
  • LANDONI, M.F., CUNNINGHAM, F.M. & LEES, P. (1995). Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. J. Vet. Pharmacol. Ther., 18, 315324.
  • LANDONI, M.F. & LEES, P. (1995). Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. Equine Vet. J., 27, 247256.
  • LASCELLES, B.D., HENDERSON, A.J. & HACKETT, I.J. (2001). Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. J. Small Anim. Pract., 42, 587593.
  • LEES, P. (2003). Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology, 11, 385399.
  • LEVY, G. (1993). The case for preclinical pharmacodynamics. In: Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development. ed. Yacobi, A., Skelly, J.P., Shah, V.P. & Benet, L.Z. New York and London: Plenum Press, pp. 713.
  • LEVY, G. (1998). Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin. Pharmacokinet., 34, 323333.
  • PINARDI, G., SIERRALTA, F. & MIRANDA, H.F. (2003). Atropine reverses the antinociception of nonsteroidal anti-inflammatory drugs in the tail-flick test of mice. Pharmacol. Biochem. Behav., 74, 603608.
  • RIENDEAU, D., PERCIVAL, M.D., BRIDEAU, C., CHARLESON, S., DUBE, D., ETHIER, D., FALGUEYRET, J.P., FRIESEN, R.W., GORDON, R., GREIG, G., GUAY, J., MANCINI, J., OUELLET, M., WONG, E., XU, L., BOYCE, S., VISCO, D., GIRARD, Y., PRASIT, P., ZAMBONI, R., RODGER, I.W., GRESSER, M., FORD-HUTCHINSON, A.W., YOUNG, R.N. & CHAN, C.C. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther., 296, 558566.
  • SANDRINI, M., VITALE, G. & PINI, L.A. (2002). Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res., 51, 154159.
  • SHIROTA, H., KOBAYASHI, S., SHIOJIRI, H. & IGARASHI, T. (1984). Determination of inflamed paw surface temperature in rats. J. Pharmacol. Methods, 12, 3543.
  • SLINGSBY, L.S. & WATERMAN-PEARSON, A.E. (2000). Postoperative analgesia in the cat after ovariohysterectomy by use of carprofen, ketoprofen, meloxicam or tolfenamic acid. J. Small Anim. Pract., 41, 447450.
  • TORRES-LOPEZ, J.E., LOPEZ-MUNOZ, F.J., CASTANEDA-HERNANDEZ, G., FLORES-MURRIETA, F.J. & GRANADOS-SOTO, V. (1997). Pharmacokinetic–pharmacodynamic modelling of the antinociceptive effect of diclofenac in the rat. J. Pharmacol. Exp. Ther., 282, 685690.
  • TOUTAIN, P.L. (2002). Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS Pharm. Sci., 4, (article 38) http://www.aapspharmsci.org/view.aspart=ps04043.
  • TOUTAIN, P.L., AUTEFAGE, A., LEGRAND, C. & ALVINERIE, M. (1994). Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. J. Vet. Pharmacol. Ther., 17, 459469.
  • TOUTAIN, P.L., CESTER, C.C., HAAK, T. & LAROUTE, V. (2001). A pharmacokinetic/pharmacodynamic approach vs a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. J. Vet. Pharmacol. Ther., 24, 4355.
  • TURCK, D., ROTH, W. & BUSCH, U. (1996). A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheumatol., 35 (Suppl 1), 1316.
  • WALKER, J.S. (1995). Pharmacokinetic–pharmacodynamic correlations of analgesics. In: Handbook of Pharmacokinetic/Pharmacodynamic Correlation. ed. Derendorf, H., Hochhaus, G. U.S.A.: CRC Press LLC, pp. 157168.
  • WISE, M.E. (1985). Negative power functions of time in pharmacokinetics and their implications. J. Pharmacokinet. Biopharm., 13, 309346.
  • YAMAOKA, K., NAKAGAWA, T. & UNO, T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6, 165175.
  • ZHANG, Y., SHAFFER, A., PORTANOVA, J., SEIBERT, K. & ISAKSON, P.C. (1997). Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther., 283, 10691075.